Insulin sensitisers and prompt revascularisation offer little cost benefit

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.592, 2009-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early insulin for VLBW neonates: little clinical benefit

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Insulin-sensitisers in the treatment of polycystic ovary syndrome

By Teede Helena J Meyer C Norman RJ

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2419-2427

Informa Healthcare

Access to resources Recommend Favorite

What has prevented the expansion of insulin sensitisers?

By Colca Jerry R Kletzien Rolf F

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 205-210

Informa Healthcare

Access to resources Recommend Favorite

Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches

By Rondinone Cristina M

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 2, 2005-04 ,pp. : 415-418

Informa Healthcare

Access to resources Recommend Favorite

Revascularisation cost effective in the long term?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 251, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite